A new treatment for ulcerative colitis: Intracolonic Bifidobacterium and xyloglucan application

Basit Öğe Kaydı
dc.authorid0000-0001-7430-8452en_US
dc.contributor.authorBozkurt, Hüseyin Sancar
dc.contributor.authorKara, Banu
dc.date.accessioned2024-07-12T21:43:18Z
dc.date.available2024-07-12T21:43:18Z
dc.date.issued2020en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractUlcerative colitis (UC) pathogenesis includes the altered gut microbiota, environmental factors, and human immune and genetic predisposition. Recently, its association with reduced bifidobacteria quantity in the microbiota is reported. Xyloglucan, a plant-based prebiotic oligosaccharide, causes increase in bifidobacteria quantity. In this article, we share the results of our UC cases treated by intracolonic single-dose administration ofBifidobacterium animalissubsp.lactisand xyloglucan combination. Intracolonic single-dose administration of 200 billion colony-forming units (CFUs) ofB. animalissubsp.lactisand 4 g of xyloglucan combination was administrated to 10 severe UC patients, who were either unresponsive or had inadequate response to treatment. All patients continued treatment after the procedure. Treatment responses were evaluated by colonoscopic, laboratory, and clinical examination after 6 weeks. Intracolonic single-dose administration ofB. animalissubsp.lactisand xyloglucan was found effective in the mucosal healing and resolution of colonic symptoms in UC patients. Intracolonic administration ofB. animalissubsp.lactisand xyloglucan in UC is a new single-strain and strain-specific prebiotic combination method. It is easy to apply and has no observable side effect. Its effectiveness on mucosal healing could be attributed to the enhancement of non-stimulatory status and biodiversity in colonic mucosa. Nonetheless, it is still necessary to develop diagnostic strategies to determine the patients to whom this method would be the most applicable.en_US
dc.identifier.citationBozkurt, H. S. ve Kara, B. (2020). A new treatment for ulcerative colitis: Intracolonic Bifidobacterium and xyloglucan application. European Journal of Inflammation, SageJournals. 18.en_US
dc.identifier.doi10.1177/2058739220942626
dc.identifier.issn2058-7392
dc.identifier.scopus2-s2.0-85089423586en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.urihttps://journals.sagepub.com/doi/full/10.1177/2058739220942626
dc.identifier.urihttps://doi.prg/10.1177/2058739220942626
dc.identifier.urihttps://hdl.handle.net/20.500.12415/7574
dc.identifier.volume18en_US
dc.identifier.wosWOS:000553678700001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherSageJournalsen_US
dc.relation.ispartofEuropean Journal of Inflammationen_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsCC0 1.0 Universal*
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.snmzKY00855
dc.subjectBifidobacteriumen_US
dc.subjectprebioticen_US
dc.subjectulcerative colitisen_US
dc.subjectxyloglucanen_US
dc.titleA new treatment for ulcerative colitis: Intracolonic Bifidobacterium and xyloglucan applicationen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu